HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wolfe, T. Articles by von Herrath, M. G. Search for Related Content PubMed PubMed Citation Articles by Wolfe, T. Articles by von Herrath, M. G.

Reduction of Antiviral CD8 Lymphocytes In Vivo with Dendritic Cells Expressing Fas Ligand—Increased Survival of Viral (Lymphocytic Choriomeningitis Virus) Central Nervous System Infection¹

Tom Wolfe^*, Chrystelle Asseman^*, Anna Hughes^*, Hiroyuki Matsue, Akira Takashima and Matthias G. von Herrath^2,*

^* Division of Immune Regulation La Jolla Institute for Allergy and Immunology 10355 Science Center Drive San Diego, CA 92121; and Department of Dermatology University of Texas Southwestern Medical Center, Dallas, TX 75235

In vivo administration of APC expressing Fas ligand (Fas-L⁺ dendritic cells (DCs)) has shown promise in dampening allergic reactions and transplant rejection. Since the effect in these studies was mainly on CD4 lymphocytes, our goal was to evaluate the ability of such killer DCs to eliminate antiviral CD8 lymphocytes and in this way ameliorate viral immunopathology or, conversely, impede viral clearance. Intravenous administration of Fas-L⁺ DCs resulted in a 50% reduction of lytic CD8 precursors following intracerebral infection with lymphocytic choriomeningitis virus (LCMV), and accordingly, immunopathology and survival of LCMV meningitis were improved, whereas viral clearance remained unaffected. In transfer studies the effect of the Fas-L⁺ DCs was only quantifiable on experienced, not naive, CD8 lymphocytes. Importantly, loading of Fas-L⁺ DCs with viral Ag before therapy was not necessary to achieve this effect, indicating that non-LCMV-infected Fas-L⁺ DCs acquired viral Ag during acute LCMV infection in vivo. Our studies delineate important aspects for the clinical use of Fas-L⁺ DCs in vivo. One should expect that they acquire viral Ags and suppress antiviral CD8 responses to some degree when given while an acute infection is ongoing. In terms of safety it is encouraging that resolution of the infection, at least in the case of LCMV, is not inhibited.

This article has been cited by other articles:

				C. Schutz, M. Fleck, A. Mackensen, A. Zoso, D. Halbritter, J. P. Schneck, and M. Oelke Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells Blood, April 1, 2008; 111(7): 3546 - 3552. [Abstract] [Full Text] [PDF]

				S. Hoves, S. W. Krause, D. Halbritter, H.-G. Zhang, J. D. Mountz, J. Scholmerich, and M. Fleck Mature But Not Immature Fas Ligand (CD95L)-Transduced Human Monocyte-Derived Dendritic Cells Are Protected from Fas-Mediated Apoptosis and Can Be Used as Killer APC J. Immunol., June 1, 2003; 170(11): 5406 - 5413. [Abstract] [Full Text] [PDF]